Reven Selects APCER Life Sciences as Its Service Provider in Pharmacovigilance, Safety Monitoring, Quality Assurance and Regulatory Affairs for Its Upcoming COVID-19 Clinical Trial

APCER Life Sciences is delighted to announce its partnership with Reven to support them in pharmacovigilance, safety monitoring, quality assurance and regulatory affairs services for its COVID-19 clinical project. Reven is planning to initiate a randomized, double-blind, placebo-controlled, multi-institutional clinical trial of the anti-inflammatory/anti-oxidant investigational drug product Rejuveinix (RJX) in the treatment of COVID-19. The clinical study is designed to compare the best available standard of care combined with a placebo to a combination of the standard of care with RJX in the treatment of COVID-19.

This partnership with Reven will help maximize patient safety and optimize regulatory oversight during the COVID-19 study; this engagement is testament to our strong scientific and medical expertise and commitment to support biotech & pharma companies’ efforts in exploring potential therapies for treatment of COVID-19.

Click here to read more about Reven and APCER partnership.